Trasylol


Also found in: Dictionary.

Trasylol

 [tras´-lol]
trademark for a preparation of aprotinin, an antihemorrhagic agent.

Trasylol

(trăs′ə-lŏl)
A trademark for the drug aprotinin.

Trasylol

[tras′ilol]
a trademark for a preparation of aprotinin, an antihemorrhagic agent.

aprotinin

A bovine polypeptide and protease inhibitor with antifibrinolytic activity that derives from basic pancreatic trypsin inhibitor (BPTI), which was added to fibrinogen in “fibrin glue”, theoretically enhancing the persistence of the fibrin clot.

It was pulled from the international market in 2007, given the concern that aprotinin increased the risk of complications and death during surgery. In 2012 the European Medicines Agency concluded that the benefits outweighed the risks, and recommended the suspension be lifted.

Trasylol

A brand name for APROTININ.
References in periodicals archive ?
Under a limited use agreement, access to Trasylol is limited, to investigational use of the drug according to the procedures described in a special treatment protocol.
The Food and Drug Administration said last week that Bayer had notified the agency that it would begin removing remaining Trasylol stock from the U.
Most notably, she has served as national trial counsel in major multidistrict litigation involving pharmaceutical product liability, including the Vioxx, Trasylol and YAZ/Yasmin matters.
Nordic Group announced today that it has reached an agreement with Bayer HealthCare in which Nordic will acquire Trasylol (aprotinin injection) worldwide excluding the United States.
He was appointed to the Trasylol Plaintiffs' Steering Committee ("PSC") Executive Committee by the Hon.
Blood was collected, using a Vacutainer[R] system, directly into 4 tubes of each of the tube-types studied: lithium heparin with 2000 U/tube of trasylol (L), citrate (C), EDTA (E), serum clot-activator (S), and serum separator (SST) tubes (BD Vacutainer[R] Blood Collection Tubes).
has agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death.
Bayer AG apologized to US regulators for withholding information about the risks of its drug Trasylol last year, urging that the treatment used in heart bypass surgery be permitted to remain on the market.
Trasylol was designed by Bayer to reduce bleeding during open-heart surgery.
The drug, aprotinin, sold under the brand name Trasylol, is widely used to prevent or reduce blood loss during the surgery.
The withdrawal of Trasylol is a notable setback for the company, especially following the withdrawal of Baycol/Lipobay around six years earlier.
Jensen represents hundreds of persons who have claims against Bayer for the withdrawn drug Trasylol and hundreds of persons with claims against GlaxoSmithKline for the withdrawn drug Avandia.